Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation

Table 2

Analysis of EV concentrations in cancer patients and healthy volunteers.

	EVs/μl (CI 95%)	value
Total EV
Controls	5207 (1751–13531)
Cancer	14308 (4368–70763)	0.000001
Lung cancer	9600 (3867–75021)	0.0001
Colorectal cancer	19044 (5257–1745393)	0.000001
Breast cancer	17437 (8079-NE)	0.001
Other	19012 (8047-NE)	0.0000001
CD31+
Controls	70 (7–268)
Cancer	168 (0.5–1297)	0.001
Lung cancer	123 (5–1021)	0.058
Colorectal cancer	168 (1–2826)	0.007
Breast cancer	371 (39-NE)	0.003
Other	411 (0-NE)	0.001
CD90-CD29+
Controls	150 (11–1573)
Cancer	168 (1–2924)	0.668
Lung cancer	297 (10–2467)	0.165
Colorectal cancer	279 (0–4347)	0.515
Breast cancer	39 (23-NE)	0.02
Other	83 (0-NE)	0.273
CD326-CD133+
Controls	34 (0–260)
Cancer	194 (0–2286)	0.00001
Lung cancer	151 (4–3376)	0.001
Colorectal cancer	123 (0–2827)	0.006
Breast cancer	262 (55-NE)	0.003
Other	300 (0-NE)	0.00001
CD326 + CD133-
Controls	742 (20–2545)
Cancer	554 (15–2546)	0.155
Lung cancer	650 (50–2188)	0.476
Colorectal cancer	899 (5–7678)	0.775
Breast cancer	150 (10-NE)	0.003
Other	177 (0-NE)	0.015
LEUKO-EV
Controls	238 (37–1721)
Cancer	265 (42–1351)	0.529
Lung cancer	328 (34–1680)	0.086
Colorectal cancer	274 (47–2416)	0.522
Breast cancer	66 (38-NE)	0.036
Other	182 (64-NE)	0.407
CD90 + CD29-
Controls	280 (24–3341)
Cancer	143 (6–5606)	0.161
Lung cancer	62 (0–2276)	0.058
Colorectal cancer	145 (8.2–17356)	0.437
Breast cancer	193 (24-NE)	0.342
Other	182 (17-NE)	0.980
CD90 + CD29+
Controls	134 (11–571)
Cancer	84 (0–615)	0.110
Lung cancer	87 (0–675)	0.232
Colorectal cancer	109 (7–788)	0.543
Breast cancer	9 (0-NE)	0.001
Other	82 (6-NE)	0.160
CD326 + CD133+
Controls	17 (0–83)
Cancer	63 (0–739)	0.124
Lung cancer	172 (0–1312)	0.002
Colorectal cancer	87 (0–2670)	0.204
Breast cancer	0 (0-NE)	0.002
Other	5 (0-NE)	0.435